Ra Pharmaceuticals (Ra Pharmaceuticals) Operating Income : $-106.98 Mil (TTM As of Dec. 2019)

View and export this data going back to 2016. Start your Free Trial

What is Ra Pharmaceuticals Operating Income?

Ra Pharmaceuticals's Operating Income for the three months ended in Dec. 2019 was $-37.83 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2019 was $-106.98 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Ra Pharmaceuticals's Operating Income for the three months ended in Dec. 2019 was $-37.83 Mil. Ra Pharmaceuticals's Revenue for the three months ended in Dec. 2019 was $0.00 Mil. Therefore, Ra Pharmaceuticals's Operating Margin % for the quarter that ended in Dec. 2019 was %.

Ra Pharmaceuticals's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Ra Pharmaceuticals's annualized ROC % for the quarter that ended in Dec. 2019 was -1,455.83%. Ra Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2019 was -2,022.21%.

Ra Pharmaceuticals Operating Income Historical Data

The historical data trend for Ra Pharmaceuticals's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ra Pharmaceuticals Operating Income Chart

Ra Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Operating Income

Get a 7-Day Free Trial

-13.36

-28.02

-55.03

-66.39

-106.98

Ra Pharmaceuticals Quarterly Data
	Dec14	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19
Operating Income	Get a 7-Day Free Trial														-16.66	-20.09	-22.85	-26.22	-37.83

Ra Pharmaceuticals Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Dec. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-106.98 Mil.

Ra Pharmaceuticals (NAS:RARX) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Ra Pharmaceuticals's annualized ROC % for the quarter that ended in Dec. 2019 is calculated as:

	ROC % (Q: Dec. 2019 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2019 )	+	Invested Capital (Q: Dec. 2019 ))	/ count )
=	-151.312 * ( 1 - 0% )	/	( (9.745	+	11.042)	/ 2 )
=	-151.312	/	10.3935
=	-1,455.83 %

where

	Invested Capital		(Q: Sep. 2019 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	308.938	-	10.679	-	( 292.602	-	max(0, 11.666	-	300.18	+	292.602	))
=	9.745

	Invested Capital		(Q: Dec. 2019 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	284.152	-	16.995	-	( 264.992	-	max(0, 18.579	-	274.694	+	264.992	))
=	11.042

Note: The Operating Income data used here is four times the quarterly (Dec. 2019) data.

2. Joel Greenblatt's definition of Return on Capital:

Ra Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2019 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2019 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2019		Q: Dec. 2019
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-151.312	/	( ( (7.124 + max(-3.101, 0))	+	(7.841 + max(-7.293, 0)) )	/	2 )
=	-151.312	/	( ( 7.124	+	7.841 )	/	2 )
=	-151.312	/	7.4825
=	-2,022.21 %

where Working Capital is:

	Working Capital		(Q: Sep. 2019 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	7.578)	-	(10.679	+	0	+	0)
=	-3.101

	Working Capital		(Q: Dec. 2019 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	9.702)	-	(16.995	+	0	+	0)
=	-7.293

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2019) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Ra Pharmaceuticals's Operating Margin % for the quarter that ended in Dec. 2019 is calculated as:

Operating Margin %	=	Operating Income (Q: Dec. 2019 )	/	Revenue (Q: Dec. 2019 )
	=	-37.828	/	0
	=	%

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

Ra Pharmaceuticals Operating Income Related Terms

Thank you for viewing the detailed overview of Ra Pharmaceuticals's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Ra Pharmaceuticals (Ra Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ra Pharmaceuticals Inc (NAS:RARX) » Definitions » Operating Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

87 Cambridge Park Drive, Cambridge, MA, USA, 02140

Website

http://www.rapharma.com

Ra Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It discovers and develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. Geographically business of the firm can be seen amplifying in the United States, Europe and even at international level.

Executives

Peter Kolchinsky	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Edward T Mathers	director	C/O MEDIMMUNE, INC., ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Timothy R Pearson	director	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Aoife Brennan	director	200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139
Douglas A Treco	director, officer: President and CEO	87 CAMBRIDGEPARK DRIVE, C/O RA PHARMACEUTICALS, INC., CAMBRIDGE MA 02140
Nea Partners 13, Limited Partnership	10 percent owner	1119 ST. PAUL STREET, BALTIMORE MD 21202
Nea 13 Gp, Ltd	10 percent owner	1119 ST. PAUL STREET, BALTIMORE MD 21202
New Enterprise Associates 13 Lp	10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202
Rajeev M. Shah	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Alexander Cumbo	director	215 FIRST STREET, SUITE 415, CAMBRIDGE MA 02142
Robert Heft	director	87 CAMBRIDGEPARK DRIVE, C/O RA PHARMACEUTICALS, INC., CAMBRIDGE MA 02140
Patrick J Kerins	10 percent owner
Ra Capital Management, L.p.	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
David Charles Lubner	officer: Executive VP and CFO	C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472